GLUE

In the past six months, Monte Rosa Therapeutics (GLUE) experienced several key stock events: H.C. Wainwright & Co. initiated 'Buy' coverage with a $25 price target in October 2026, citing the company as undervalued. Also in October 2026, the company announced positive Phase 1 GFORCE-1 study results for MRT-8102, showing rapid and sustained NEK7 degradation and broad reductions in inflammatory biomarkers. In September 2026, Novartis initiated a Phase 2 study of MRT-6160, triggering a $50 million milestone payment to Monte Rosa. August 2026 saw the first patient dosed in the Phase 2 MODeFIRe-1 trial for MRT-2359, but the company also reported a Q2 2026 loss, missing revenue estimates. In June 2026, a chief medical officer sold approximately $882,000 worth of shares. March 2026 results for Q4 and full-year 2025 highlighted positive interim MRT-8102 Phase 1 data with an 85% CRP reduction, and the company closed a $345 million financing extending its cash runway into 2029, despite a significant drop in Q4 2025 collaboration revenue and a widened net loss. As of September 18, 2026, the stock price was $12.13 per share, marking an 85.76% increase from September 22, 2025, but a 42.92% decline over the last six months.